NEW YORK: SK Capital Partners LP, a New York-based private investment firm specializing in specialty materials, ingredients, and life sciences sectors, announced Thursday it has entered into exclusive negotiations to acquire LISI Group’s medical division, Lisi Medical.
The proposed deal, still subject to antitrust and foreign investment reviews, as well as employee consultation processes, is expected to close in the second half of 2025.
Lisi Medical, headquartered across two sites in Minnesota and two in France, manufactures high-precision metal components for medical devices. Its portfolio includes instruments used in robotic-assisted and minimally invasive surgeries, along with orthopedic implants.
“We feel privileged to partner with LISI Group to acquire Lisi Medical,” said Josh Lieberman, principal at SK Capital. “The company’s cutting-edge technologies and deep engineering heritage position it as a critical solutions provider to top-tier MedTech OEMs.”
SK Capital expressed plans to accelerate Lisi Medical’s growth by enhancing automation, expanding capacity, and developing new capabilities—both organically and through mergers and acquisitions.
“Lisi Medical fits strongly within our portfolio,” said Aaron Davenport, managing director at SK Capital. “We have long-standing experience in life sciences CDMOs and have successfully carved out businesses into thriving platforms.”
Emmanuel Viellard, CEO of LISI Group, called the partnership a strategic move to support Lisi Medical’s continued evolution. “SK Capital’s track record and financial strength make them an ideal partner to lead the company’s next chapter,” Viellard said.
Legal and financial advisory firms involved in the transaction include Kirkland & Ellis, Piper Sandler & Co., Jefferies LLC, Sycomore Corporate Finance, Rothschild & Co, and Dentons. Partners Group will provide committed debt financing.